{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:52:09Z","timestamp":1771617129110,"version":"3.50.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00115-015-4306-9","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T08:33:59Z","timestamp":1430728439000},"page":"725-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Morbus Huntington","Huntington\u2019s disease"],"prefix":"10.1007","volume":"86","author":[{"given":"J.D.","family":"Rollnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"4306_CR1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","volume":"57","author":"Adair","year":"2001","unstructured":"Adair JC, Knoefel JE, Morgan N (2001) Controlled trial of N-acetylcysteine for patients with probable Alzheimer\u2019s disease. Neurology 57:1515\u20131517","journal-title":"Neurology"},{"key":"4306_CR2","doi-asserted-by":"crossref","first-page":"RRN1261","DOI":"10.1371\/currents.RRN1261","volume":"3","author":"Anderson","year":"2011","unstructured":"Anderson K, Craufurd D, Edmondson MC et al (2011) An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington\u2019s disease. PLoS Curr 3:RRN1261","journal-title":"PLoS Curr"},{"key":"4306_CR3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597\u2013603","journal-title":"Neurology"},{"key":"4306_CR4","doi-asserted-by":"crossref","first-page":"e1002481","DOI":"10.1371\/journal.pgen.1002481","volume":"8","author":"Ba\u00f1ez-Coronel","year":"2012","unstructured":"Ba\u00f1ez-Coronel M, Porta S, Kagerbauer B et al (2012) A pathogenic mechanism in Huntington\u2019s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8:e1002481","journal-title":"PLoS Genet"},{"key":"4306_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","volume":"29","author":"Beglinger","year":"2014","unstructured":"Beglinger LJ, Adams WH, Langbehn D et al (2014) Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 29:401\u2013405","journal-title":"Mov Disord"},{"key":"4306_CR6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"Borrell-Pag\u00e8s","year":"2006","unstructured":"Borrell-Pag\u00e8s M, Canals JM, Cordeli\u00e8res FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116:1410\u20131424","journal-title":"J Clin Invest"},{"key":"4306_CR7","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S et al (2011) An international survey-based algorithm for the pharmacologic treatment of Chorea in Huntington\u2019s disease. Version 2. PLoS Curr 3:RRN1260","journal-title":"PLoS Curr"},{"key":"4306_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbr.2014.01.048","volume":"264","author":"Chakraborty","year":"2014","unstructured":"Chakraborty J, Nthenge-Ngumbau DN, Rajamma U, Mohanakumar KP (2014) Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease. Behav Brain Res 264:91\u2013104","journal-title":"Behav Brain Res"},{"key":"4306_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cns.12189","volume":"20","author":"Chakraborty","year":"2014","unstructured":"Chakraborty J, Singh R, Dutta D et al (2014) Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease. CNS Neurosci Ther 20:10\u201319","journal-title":"CNS Neurosci Ther"},{"key":"4306_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mds.25835","volume":"29","author":"Chandra","year":"2014","unstructured":"Chandra A, Johri A, Beal MF (2014) Prospects for neuroprotective therapies in prodromal Huntington\u2019s disease. Mov Disord 29:285\u2013293","journal-title":"Mov Disord"},{"key":"4306_CR11","first-page":"3312","volume":"9","author":"Chow","year":"2003","unstructured":"Chow HH, Cai Y, Hakim IA et al (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9:3312\u20133319","journal-title":"Clin Cancer Res"},{"key":"4306_CR12","first-page":"1","volume":"16","author":"Ciancarelli","year":"2014","unstructured":"Ciancarelli I, De Amicis D, Di Massimo C et al (2014) Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington\u2019s disease. Funct Neurol 16:1\u20136","journal-title":"Funct Neurol"},{"key":"4306_CR13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819\u2013829","journal-title":"N Engl J Med"},{"key":"4306_CR14","first-page":"220","volume":"5","author":"Copped\u00e8","year":"2014","unstructured":"Copped\u00e8 F (2014) The potential of epigenetic therapies in neurodegenerative diseases. Front Genet 5:220","journal-title":"Front Genet"},{"key":"4306_CR15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11825-011-0284-x","volume":"23","author":"Deutsche","year":"2011","unstructured":"Deutsche Gesellschaft f\u00fcr Humangenetik, Berufsverband Deutscher Humangenetiker (2011) S2k-Leitlinie Humangenetische Diagnostik und Beratung. Medgen 23:281\u2013323","journal-title":"Medgen"},{"key":"4306_CR16","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (DGN). Leitlinie Chorea. AWMF-Leitlinie Nr. 030\/028 2011. http:\/\/www.awmf.org"},{"key":"4306_CR17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"Di","year":"2012","unstructured":"Di Pardo A, Maglione V, Alpaugh M et al (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109:3528\u20133533","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4306_CR18","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"Di","year":"2014","unstructured":"Di Pardo A, Amico E, Favellato M et al (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 23:2251\u20132265","journal-title":"Hum Mol Genet"},{"key":"4306_CR19","doi-asserted-by":"crossref","first-page":"e29522","DOI":"10.1371\/journal.pone.0029522","volume":"7","author":"Dorsey","year":"2012","unstructured":"Dorsey E, Huntington Study Group COHORT Investigators (2012) Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One 7:e29522","journal-title":"PLoS One"},{"key":"4306_CR20","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","volume":"15","author":"Ehrnhoefer","year":"2006","unstructured":"Ehrnhoefer DE, Duennwald M, Markovic P et al (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet 15:2743\u20132751","journal-title":"Hum Mol Genet"},{"key":"4306_CR21","doi-asserted-by":"crossref","first-page":"e16172","DOI":"10.1371\/journal.pone.0016172","volume":"6","author":"Ellrichmann","year":"2011","unstructured":"Ellrichmann G, Petrasch-Parwez E, Lee DH et al (2011) Efficacy of fumaric acid esters in the R6\/2 and YAC128 models of Huntington\u2019s disease. PLoS One 6:e16172","journal-title":"PLoS One"},{"key":"4306_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157015910792246155","volume":"8","author":"Esposito","year":"2010","unstructured":"Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8:228\u2013242","journal-title":"Curr Neuropharmacol"},{"key":"4306_CR23","unstructured":"Gasser T (1998) Chorea Huntington und Chorea Sydenham. In: Brandt T, Dichgans J, Diener HC (Hrsg) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, S\u00a0915\u2013921"},{"key":"4306_CR24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo PS, Christie BR (2014) The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates? Curr Drug Targets 15:454\u2013468","journal-title":"Curr Drug Targets"},{"key":"4306_CR25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","volume":"121","author":"Gonzalez","year":"2014","unstructured":"Gonzalez V, Cif L, Biolsi B, Garcia-Ptacek S et al (2014) Deep brain stimulation for Huntington\u2019s disease: long-term results of a prospective open-label study. J Neurosurg 121:114\u2013122","journal-title":"J Neurosurg"},{"key":"4306_CR26","doi-asserted-by":"crossref","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","volume":"3","author":"Groves","year":"2011","unstructured":"Groves M, Duijn E van, Anderson K et al (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington\u2019s Disease. PLoS Curr 3:RRN1259","journal-title":"PLoS Curr"},{"key":"4306_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","volume":"29","author":"Gusella","year":"2014","unstructured":"Gusella JF, MacDonald ME, Lee JM (2014) Genetic modifiers of Huntington\u2019s disease. Mov Disord 29:1359\u20131365","journal-title":"Mov Disord"},{"key":"4306_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","volume":"41","author":"Hathorn","year":"2011","unstructured":"Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis 41:43\u201350","journal-title":"Neurobiol Dis"},{"key":"4306_CR29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology 66:250\u2013252","journal-title":"Neurology"},{"key":"4306_CR30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1326-7-12","volume":"7","author":"Hickey","year":"2012","unstructured":"Hickey MA, Zhu C, Medvedeva V et al (2012) Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington\u2019s disease. Mol Neurodegener 7:12","journal-title":"Mol Neurodegener"},{"key":"4306_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"Holl","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A et al (2010) Combating depression in Huntington\u2019s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 25:46\u201350","journal-title":"Int Clin Psychopharmacol"},{"key":"4306_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamaneurol.382","volume":"70","author":"HORIZON","year":"2013","unstructured":"HORIZON Investigators of the Huntington Study Group and European Huntington\u2019s Disease Network (2013) A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol 70:25\u201333","journal-title":"JAMA Neurol"},{"key":"4306_CR33","first-page":"317","volume":"26","author":"Huntington","year":"1872","unstructured":"Huntington GS (1872) On Chorea. Med Surg Rep Philadelph 26:317\u2013321","journal-title":"Med Surg Rep Philadelph"},{"key":"4306_CR34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington","year":"1993","unstructured":"Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"4306_CR35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord 11:136\u2013142","journal-title":"Mov Disord"},{"key":"4306_CR36","first-page":"397","volume":"57","author":"Huntington","year":"2001","unstructured":"Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology 57:397\u2013404","journal-title":"Neurology"},{"key":"4306_CR37","first-page":"1582","volume":"65","author":"Huntington","year":"2008","unstructured":"Huntington Study Group (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582\u20131589","journal-title":"Arch Neurol"},{"key":"4306_CR38","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/mds.22408","volume":"25","author":"Huntington","year":"2010","unstructured":"Huntington Study Group Pre2CARE Investigators (2010) Safety and tolerability of high-dosage coenzyme Q10 in Huntington\u2019s disease and healthy subjects. Mov Disord 25:1924\u20131928","journal-title":"Mov Disord"},{"key":"4306_CR39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","volume":"14","author":"Huntington","year":"2015","unstructured":"Huntington Study Group Reach2HD Investigators (2015) Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 14:39\u201347","journal-title":"Lancet Neurol"},{"key":"4306_CR40","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1093\/hmg\/ddt098","volume":"22","author":"Jiang","year":"2013","unstructured":"Jiang M, Peng Q, Liu X et al (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington\u2019s disease. Hum Mol Genet 22:2462\u20132470","journal-title":"Hum Mol Genet"},{"key":"4306_CR41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"Jiang","year":"2012","unstructured":"Jiang M, Wang J, Fu J et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18:153\u2013158","journal-title":"Nat Med"},{"key":"4306_CR42","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1093\/hmg\/ddq148","volume":"19","author":"Johnson","year":"2010","unstructured":"Johnson CD, Davidson BL (2010) Huntington\u2019s disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 19:R98\u2013R102","journal-title":"Hum Mol Genet"},{"key":"4306_CR43","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.26003","volume":"29","author":"Kalliolia","year":"2014","unstructured":"Kalliolia E, Silajd\u017ei\u0107 E, Nambron R et al (2014) Plasma melatonin is reduced in Huntington\u2019s disease. Mov Disord 29:1511\u20131515","journal-title":"Mov Disord"},{"key":"4306_CR44","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Kieburtz","year":"2013","unstructured":"Kieburtz K, McGarry A, McDermott M et al (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord 28:1407\u20131415","journal-title":"Mov Disord"},{"key":"4306_CR45","doi-asserted-by":"crossref","first-page":"e30903","DOI":"10.1371\/journal.pone.0030903","volume":"7","author":"Kloos","year":"2012","unstructured":"Kloos AD, Kegelmeyer DA, White SE, Kostyk SK (2012) The impact of different types of assistive devices on gait measures and safety in Huntington\u2019s disease. PLoS One 7:e30903","journal-title":"PLoS One"},{"key":"4306_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","volume":"62","author":"Kumar","year":"2010","unstructured":"Kumar P, Kalonia H, Kumar A (2010) Huntington\u2019s disease: pathogenesis to animal models. Pharmacol Rep 62:1\u201314","journal-title":"Pharmacol Rep"},{"key":"4306_CR47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","volume":"38","author":"Labbadia","year":"2013","unstructured":"Labbadia J, Morimoto RI (2013) Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378\u2013385","journal-title":"Trends Biochem Sci"},{"key":"4306_CR48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.53.4.801","volume":"53","author":"Laccone","year":"1999","unstructured":"Laccone F, Engel U, Holinski-Feder E et al (1999) DNA analysis of Huntington\u2019s disease: five years of experience in Germany, Austria, and Switzerland. Neurology 53:801\u2013806","journal-title":"Neurology"},{"key":"4306_CR49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1471-4159.2009.06331.x","volume":"111","author":"Lagoa","year":"2009","unstructured":"Lagoa R, Lopez-Sanchez C, Samhan-Arias AK et al (2009) Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. J Neurochem 111:473\u2013487","journal-title":"J Neurochem"},{"key":"4306_CR50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, Dubois B, Y\u00e9benes JG de et al (2007) Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study. Ann Neurol 62:262\u2013272","journal-title":"Ann Neurol"},{"key":"4306_CR51","doi-asserted-by":"crossref","first-page":"22558","DOI":"10.3390\/ijms141122558","volume":"14","author":"Lauterbach","year":"2013","unstructured":"Lauterbach EC (2013) Neuroprotective effects of psychotropic drugs in Huntington\u2019s disease. Int J Mol Sci 14: 22558\u201322603","journal-title":"Int J Mol Sci"},{"key":"4306_CR52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"Lee","year":"2012","unstructured":"Lee JM, Ramos EM, Lee JH et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690\u2013695","journal-title":"Neurology"},{"key":"4306_CR53","first-page":"579","volume":"31","author":"Lopez","year":"2013","unstructured":"Lopez WO, Nikkhah G, Kahlert UD et al (2013) Clinical neurotransplantation protocol for Huntington\u2019s and Parkinson\u2019s disease. Restor Neurol Neurosci 31:579\u2013595","journal-title":"Restor Neurol Neurosci"},{"key":"4306_CR54","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/ejhg.2012.200","volume":"21","author":"Losekoot","year":"2013","unstructured":"Losekoot M, Belzen MJ van, Seneca S et al (2013) EMQN\/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet 21:480\u2013486","journal-title":"Eur J Hum Genet"},{"key":"4306_CR55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nbd.2014.06.022","volume":"71","author":"Lu","year":"2014","unstructured":"Lu Z, Marks E, Chen J et al (2014) Altered selenium status in Huntington\u2019s disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiol Dis 71:34\u201342","journal-title":"Neurobiol Dis"},{"key":"4306_CR56","unstructured":"L\u00fccking CH. Amtage F, Hummel S et al (2013) Huntington-Erkrankung. In: Hufschmidt A, L\u00fccking CH, Rauer S (Hrsg) Neurologie compact. Thieme-Verlag, Stuttgart, S\u00a0360\u2013364"},{"key":"4306_CR57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W et al (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12:435\u2013442","journal-title":"Lancet Neurol"},{"key":"4306_CR58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/294264","volume":"27","author":"M\u00fcller-Vahl","year":"2013","unstructured":"M\u00fcller-Vahl KR (2013) Treatment of Tourette syndrome with cannabinoids. Behav Neurol 27:119\u2013124","journal-title":"Behav Neurol"},{"key":"4306_CR59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","volume":"13","author":"Ondo","year":"2007","unstructured":"Ondo WG, Mejia NI, Hunter CB (2007) A pilot study of the clinical efficacy and safety of memantine for Huntington\u2019s disease. Parkinsonism Relat Disord 13:453\u2013454","journal-title":"Parkinsonism Relat Disord"},{"key":"4306_CR60","first-page":"RRN1184","volume":"2","author":"Orth","year":"2010","unstructured":"Orth M, Handley OJ, Schwenke C et al (2010) Observing Huntington\u2019s Disease: the European Huntington\u2019s Disease Network\u2019s REGISTRY. PLoS Curr 2:RRN1184","journal-title":"PLoS Curr"},{"key":"4306_CR61","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/mds.25997","volume":"29","author":"Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD (2014) Onset of Huntington\u2019s disease: can it be purely cognitive? Mov Disord 29:1342\u20131350","journal-title":"Mov Disord"},{"key":"4306_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.08.014","volume":"232","author":"Pasinetti","year":"2011","unstructured":"Pasinetti GM, Wang J, Marambaud P et al (2011) Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington\u2019s disease and other neurodegenerative disorders. Exp Neurol 232:1\u20136","journal-title":"Exp Neurol"},{"key":"4306_CR63","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","volume":"13","author":"Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD, Ross CA et al (2014) Prediction of manifest Huntington\u2019s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol 13:1193\u20131201","journal-title":"Lancet Neurol"},{"key":"4306_CR64","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","volume":"152","author":"Peyser","year":"1995","unstructured":"Peyser CE, Folstein M, Chase GA et al (1995) Trial of d-alpha-tocopherol in Huntington\u2019s disease. Am J Psychiatry 152:1771\u20131775","journal-title":"Am J Psychiatry"},{"key":"4306_CR65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neuropharm.2014.07.021","volume":"89","author":"Pietropaolo","year":"2015","unstructured":"Pietropaolo S, Bellocchio L, Ruiz-Calvo A et al (2015) Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington\u2019s disease. Neuropharmacology 89:368\u2013374","journal-title":"Neuropharmacology"},{"key":"4306_CR66","first-page":"5","volume":"20","author":"Piira","year":"2013","unstructured":"Piira A, Walsem MR van, Mikalsen G et al (2013) Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington\u2019s disease: a Prospective Intervention Study. PLoS Curr 20:5","journal-title":"PLoS Curr"},{"key":"4306_CR67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.26101","volume":"30","author":"Prundean","year":"2015","unstructured":"Prundean A, Youssov K, Humbert S et al (2015) A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington\u2019s disease. Mov Disord 30(2):288\u2013289","journal-title":"Mov Disord"},{"key":"4306_CR68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainresrev.2009.04.001","volume":"61","author":"Reddy","year":"2009","unstructured":"Reddy PH, Mao P, Manczak M (2009) Mitochondrial structural and functional dynamics in Huntington\u2019s disease. Brain Res Rev 61:33\u201348","journal-title":"Brain Res Rev"},{"key":"4306_CR69","unstructured":"Rie\u00df O (1998) Morbus Huntington. In: Rie\u00df O, Sch\u00f6ls L (Hrsg) Neurogenetik. Springer-Verlag, Heidelberg, S\u00a0223\u2013231"},{"key":"4306_CR70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S0317167100012671","volume":"39","author":"Rinaldi","year":"2012","unstructured":"Rinaldi C, Salvatore E, Giordano I et al (2012) Predictors of survival in a Huntington\u2019s disease population from southern Italy. Can J Neurol Sci 39:48\u201351","journal-title":"Can J Neurol Sci"},{"key":"4306_CR71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0028-1090212","volume":"36","author":"Rollnik","year":"2009","unstructured":"Rollnik JD (2009) Komplexe choreatiforme Bewegungsst\u00f6rung bei Hashimoto-Thyreoiditis. Akt Neurol 36:138\u2013140","journal-title":"Akt Neurol"},{"key":"4306_CR72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","volume":"82","author":"Rosas","year":"2014","unstructured":"Rosas HD, Doros G, Gevorkian S et al (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82:850\u2013857","journal-title":"Neurology"},{"key":"4306_CR73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000334273","volume":"9","author":"Sandhir","year":"2012","unstructured":"Sandhir R, Sood A, Mehrotra A, Kamboj SS (2012) N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington\u2019s disease. Neurodegener Dis 9:145\u2013157","journal-title":"Neurodegener Dis"},{"key":"4306_CR74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11064-014-1255-9","volume":"39","author":"Senol","year":"2014","unstructured":"Senol N, Naz\u0131ro\u011flu M, Y\u00fcr\u00fcker V (2014) N-acetylcysteine and selenium modulate oxidative stress, antioxidant vitamin and cytokine values in traumatic brain injury-induced rats. Neurochem Res 39:685\u2013692","journal-title":"Neurochem Res"},{"key":"4306_CR75","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2008.21.1284","volume":"27","author":"Shanafelt","year":"2009","unstructured":"Shanafelt TD, Call TG, Zent CS et al (2009) Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27:3808\u20133814","journal-title":"J Clin Oncol"},{"key":"4306_CR76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-140109","volume":"3","author":"Sitek","year":"2014","unstructured":"Sitek EJ, Thompson JC, Craufurd D, Snowden JS (2014) Unawareness of deficits in Huntington\u2019s disease. J Huntingtons Dis 3:125\u2013135","journal-title":"J Huntingtons Dis"},{"key":"4306_CR77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P, Nelson B et al (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233:463\u2013471","journal-title":"Exp Neurol"},{"key":"4306_CR78","doi-asserted-by":"crossref","unstructured":"S\u00fcssmuth SD, Haider S, Landwehrmeyer GB et al (2015) An exploratory double blind, randomised clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol 79(3)465\u2013476","DOI":"10.1111\/bcp.12512"},{"key":"4306_CR79","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"Tabernero","year":"2013","unstructured":"Tabernero J, Shapiro GI, LoRusso PM et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406\u2013417","journal-title":"Cancer Discov"},{"key":"4306_CR80","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1212\/01.WNL.0000160388.96242.77","volume":"64","author":"Tabrizi","year":"2005","unstructured":"Tabrizi SJ, Blamire AM, Manners DN et al (2005) High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64:1655\u20131656","journal-title":"Neurology"},{"key":"4306_CR81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1179\/1476830511Y.0000000005","volume":"14","author":"Tasset","year":"2011","unstructured":"Tasset I, Pontes AJ, Hinojosa AJ et al (2011) Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington\u2019s disease-like rat model. Nutr Neurosci 14:106\u2013111","journal-title":"Nutr Neurosci"},{"key":"4306_CR82","doi-asserted-by":"crossref","first-page":"e87923","DOI":"10.1371\/journal.pone.0087923","volume":"9","author":"Todd","year":"2014","unstructured":"Todd D, Gowers I, Dowler SJ et al (2014) A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington\u2019s disease. PLoS One 9:e87923","journal-title":"PLoS One"},{"key":"4306_CR83","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1021\/jm3015926","volume":"56","author":"Trippier","year":"2013","unstructured":"Trippier PC, Jansen Labby K et al (2013) Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem 56:3121\u20133147","journal-title":"J Med Chem"},{"key":"4306_CR84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jmg.31.5.377","volume":"31","author":"Trottier","year":"1994","unstructured":"Trottier Y, Biancalana V, Mandel JL (1994) Instability of CAG repeats in Huntington\u2019s disease: relation to parental transmission and age of onset. J Med Genet 31:377\u2013382","journal-title":"J Med Genet"},{"key":"4306_CR85","doi-asserted-by":"crossref","first-page":"358370","DOI":"10.1155\/2012\/358370","volume":"2012","author":"Vagner","year":"2012","unstructured":"Vagner T, Young D, Mouravlev A (2012) Nucleic acid-based therapy approaches for Huntington\u2019s disease. Neurol Res Int 2012:358370","journal-title":"Neurol Res Int"},{"key":"4306_CR86","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","volume":"61","author":"Verbessem","year":"2003","unstructured":"Verbessem P, Lemiere J, Eijnde BO et al (2003) Creatine supplementation in Huntington\u2019s disease: a placebo-controlled pilot trial. Neurology 61:925\u2013930","journal-title":"Neurology"},{"key":"4306_CR87","unstructured":"Visser TJ (2010) Huntington\u2019s disease. Etiology and symptoms, diagnosis and treatment. Nova Science Publishers, New York"},{"key":"4306_CR88","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-5949.2009.00105.x","volume":"15","author":"Wang","year":"2009","unstructured":"Wang X (2009) The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 15:345\u2013357","journal-title":"CNS Neurosci Ther"},{"key":"4306_CR89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12513","volume":"79","author":"Westerberg","year":"2015","unstructured":"Westerberg G, Chiesa JA, Andersen CA et al (2015) Safety, Pharmacokinetics, pharmacogenomics and QT Concentration effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. Br J Clin Pharmacol 79(3):477\u2013491","journal-title":"Br J Clin Pharmacol"},{"key":"4306_CR90","unstructured":"Weindl A, Conrad B (1996) Chorea und choreatische Bewegungsst\u00f6rungen. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsst\u00f6rungen in der Neurologie. Thieme-Verlag, Stuttgart, S\u00a0155\u2013180"},{"key":"4306_CR91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2006.00377.x","volume":"41","author":"Weishaupt","year":"2006","unstructured":"Weishaupt JH, Bartels C, P\u00f6lking E et al (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41:313\u2013323","journal-title":"J Pineal Res"},{"key":"4306_CR92","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline? Mov Disord 29:1434\u20131445","journal-title":"Mov Disord"},{"key":"4306_CR93","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","volume":"5","author":"Zielonka","year":"2014","unstructured":"Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M (2014) Skeletal muscle pathology in Huntington\u2019s disease. Front Physiol 5:380","journal-title":"Front Physiol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-015-4306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-015-4306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-015-4306-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T19:25:14Z","timestamp":1598988314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-015-4306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1007\/s00115-015-4306-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}